{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:28:13Z","timestamp":1787675293372,"version":"build-2784847793"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-Grade Serous Ovarian Carcinoma (HGSOC) and Low-Grade Serous Ovarian Carcinoma (LGSOC) are distinct subtypes of epithelial ovarian cancer with significant differences in pathogenesis and prognosis, posing challenges for precise diagnosis. Identifying reliable biomarkers is crucial for improving differential diagnosis and clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptome RNA-seq data of HGSOC and LGSOC were obtained from the GEO database (GSE27651, GSE126132). Differentially expressed immune-related genes (DIRGs) were identified. Functional enrichment analysis and protein-protein interaction (PPI) network construction were performed. The Least Absolute Shrinkage and Selection Operator (LASSO) regression and multiple Support Vector Machine Recursive Feature Elimination (mSVM-RFE) algorithms were used to select predictive genes. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves, and a nomogram was developed. Findings were validated in an independent dataset and via immunohistochemistry (IHC). The CIBERSORT algorithm assessed correlations between key DIRGs and tumor-infiltrating immune cells, with false discovery rate (FDR) correction applied for multiple testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-one DIRGs were identified in HGSOC versus LGSOC, predominantly enriched in cytokine-mediated signaling, cytokine-cytokine receptor interaction, and JAK-STAT pathways.\n                      <jats:italic>STAT1<\/jats:italic>\n                      and\n                      <jats:italic>IL-7<\/jats:italic>\n                      were selected as diagnostic biomarkers, with area under the curve (AUC) values of 0.908 and 0.842 in the train group. Respectively, validation in an independent merged cohort (GSE14001, GSE73168, GSE146965; 55 HGSOC, 13 LGSOC) yielded AUCs of 0.703 (95% CI: 0.517\u20130.889) for\n                      <jats:italic>STAT1<\/jats:italic>\n                      and 0.706 (95% CI: 0.501\u20130.912) for\n                      <jats:italic>IL-7<\/jats:italic>\n                      . IHC confirmed significantly higher\n                      <jats:italic>STAT1<\/jats:italic>\n                      and lower\n                      <jats:italic>IL-7<\/jats:italic>\n                      protein expression in HGSOC tissues (P &amp;lt; 0.05). Immune microenvironment analysis revealed that HGSOC exhibited significantly higher fractions of na\u00efve B cells, M2 macrophages, and neutrophils, and lower fractions of resting memory CD4+ T cells and eosinophils after FDR correction (all q &amp;lt; 0.05).\n                      <jats:italic>STAT1<\/jats:italic>\n                      expression was strongly positively correlated with M1 macrophages (\u03c1 = 0.688, q = 9.9\u00d710\n                      <jats:sup>-<\/jats:sup>\n                      <jats:sup>8<\/jats:sup>\n                      ), and showed correlation trends with other immune cell types that did not remain significant after FDR correction.\n                      <jats:italic>IL-7<\/jats:italic>\n                      expression exhibited a negative correlation trend with neutrophils (\u03c1 = \u20130.372, raw P\u00a0=\u00a00.0048, q = 0.100).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>STAT1<\/jats:italic>\n                      and\n                      <jats:italic>IL-7<\/jats:italic>\n                      are consistently differentially expressed between HGSOC and LGSOC and may serve as ancillary diagnostic biomarkers in histologically ambiguous cases. However, their clinical utility\u2014particularly in multi-gene combinations\u2014requires prospective validation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1779912","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:20:47Z","timestamp":1776140447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["STAT1 and IL-7 as potential diagnostic biomarkers for distinguishing high-grade from low-grade serous ovarian cancer: a multi-cohort analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhuna","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Women's Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-13-0391","article-title":"Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium","volume":"22","author":"K\u00f6bel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prevent: A Publ Am Assoc For Cancer Research Cosponsor by Am Soc Prev Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw085","article-title":"Low-grade serous carcinoma of the ovary or peritoneum","author":"Gershenson","year":"2016","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.364","article-title":"Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum","volume":"113","author":"Gershenson","year":"2015","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2024.101302","article-title":"From fallopian tube epithelium to high-grade serous ovarian cancer: a single-cell resolution review of sex steroid hormone signaling","volume":"96","author":"Gjorgoska","year":"2024","journal-title":"Prog Lipid Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690201","article-title":"Infiltration by CXCL10 secreting macrophages is associated with antitumor immunity and response to therapy in ovarian cancer subtypes","volume":"12","author":"Ardighieri","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122178","article-title":"Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation","volume":"333","author":"McKenzie","year":"2023","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102497","article-title":"Low grade serous ovarian cancer - a rare disease with increasing therapeutic options","volume":"112","author":"Zwimpfer","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104603","article-title":"The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features","volume":"208","author":"Santoro","year":"2025","journal-title":"Crit Rev Oncology\/Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adr4795","article-title":"Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer","volume":"10","author":"Slattery","year":"2025","journal-title":"Sci Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/path.6338","article-title":"Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma","volume":"264","author":"Vallejos","year":"2024","journal-title":"J Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41597-024-03869-x","article-title":"High-throughput drug screening identifies novel therapeutics for low grade serous ovarian carcinoma","volume":"11","author":"Pishas","year":"2024","journal-title":"Sci Data"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100629","article-title":"Early genetic divergence of high-grade carcinomas originating from low-grade serous ovarian neoplasms","volume":"38","author":"Chui","year":"2025","journal-title":"Modern Pathol: Off J United States Can Acad Pathol Inc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680442","article-title":"The broad immunomodulatory effects of IL-7 and its application in vaccines","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41419-025-08312-6","article-title":"IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-\u03baB\/CXCL1 axis in ovarian cancer","volume":"17","author":"Zheng","year":"2025","journal-title":"Cell Death Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265818","article-title":"The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coi.2021.02.009","article-title":"Inborn errors of STAT1 immunity","volume":"72","author":"Mizoguchi","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040430","article-title":"STAT1-deficient HPV E6\/E7-associated cancers maintain host immunocompetency against therapeutic intervention","volume":"12","author":"Lim","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638102","article-title":"M1 macrophages - unexpected contribution to tumor progression","volume":"16","author":"Kovaleva","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1963240","article-title":"Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer","volume":"36","author":"Yan","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157475","article-title":"Guizhi-Fuling Wan suppresses carcinoma-associated mesenchymal stem cells-induced ovarian cancer progression via STAT3 inhibition","volume":"148","author":"Xue","year":"2025","journal-title":"Phytomedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040697","article-title":"What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors","volume":"11","author":"De Leo","year":"2021","journal-title":"Diag (Basel Switzerland)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:20:48Z","timestamp":1776140448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1779912"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1779912","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1779912"}}